Superworth

Prime Medicine price to sales ratio PRME

Market value divided by revenue over the last twelve months, since 2025.

Today, Nov 2, 2026
198×
Peer median
3.7×

Prime Medicine's price to sales ratio is 198× as of Nov 2, 2026.

The median for 4 biotech stocks of a similar size is 3.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far198×98.8×198×
2025106×40.3×171×

Against its peers

Companies in Biotechnology nearest Prime Medicine's size, closest first, today.

CompanyPrice to sales ratio
PRMEPrime Medicine198×
MGTXMeiraGTx2.3×
VCELVericel6.8×
ADMAAdma Biologics4.8×
PLXProtalix BioTherapeutics2.6×
Peer median3.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Prime Medicine

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.